Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the second half of 2019. As more biosimilars referencing these brands become available in the United States in 2020, this year will be pivotal for stakeholders active in the U.S. oncology space to understand the dynamics of how these newly launched biosimilars will affect the coverage and uptake of their reference brands, other originator biologics, and other biosimilars. This report series will track biosimilar and brand use in the United States through real-world data and formulary analysis, with insights from prescribers and payers.
- Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 1
- Special Topics: Oncology Biosimilars in the United States - Wave 1
Author(s): Hamzah Aideed, M.Sc.
Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology.
Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an M.Sc. in Biotechnology & Business Management from the University of Warwick and a B.Sc. in Biological Chemistry from Aston University.